IN8bio Inc. (INAB) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

IN8bio Inc. (INAB)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.30

-0.02 (-5.21%)

At close: Jan 15, 2025, 12:33 PM

undefined% (undefined)

Bid	0.29
Market Cap	21.43M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.74
PE Ratio (ttm)	-0.4
Forward PE	n/a
Analyst	Buy

Ask	0.3
Volume	569,987
Avg. Volume (20D)	1,399,245
Open	0.30
Previous Close	0.32
Day's Range	0.28 - 0.32
52-Week Range	0.22 - 1.74
Beta	undefined

About INAB

IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clini...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jul 30, 2021

Employees 39

Stock Exchange NASDAQ

Ticker Symbol INAB

Website https://in8bio.com

Analyst Forecast

According to 4 analyst ratings, the average rating for INAB stock is "Buy." The 12-month stock price forecast is $7.5, which is an increase of 2436.35% from the latest price.

Buy 75.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

4 months ago · Source

-27.33%

IN8bio shares are trading lower amid a possible se... Unlock content with Pro Subscription

4 months ago · Source

-7.02%

IN8bio shares are trading higher after the company announced it will focus on generating robust clinical data from INB-100, the ongoing investigator-sponsored Phase 1 clinical trial of acute myeloid leukemia. Also, the company will preserve its cash resources with cost savings and a 49% workforce reduction.

News

10 months ago · businesswire.com

IN8bio to Present at Upcoming Investor Conferences

NEW YORK--(BUSINESS WIRE)---- $INAB #biotech--IN8bio to Present at Upcoming Investor Conferences.

1 year ago · zacks.com

Here's Why IN8bio, Inc. (INAB) Could be Great Choice for a Bottom Fisher

IN8bio, Inc. (INAB) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean ...

1 year ago · zacks.com

IN8bio, Inc. (INAB)'s Technical Outlook is Bright After Key Golden Cross

IN8bio, Inc. (INAB) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, INAB's 50-day simple moving average broke out above its 200-day ...

1 year ago · zacks.com

IN8bio, Inc. (INAB) Is Up 37.87% in One Week: What You Should Know

Does IN8bio, Inc. (INAB) have what it takes to be a top stock pick for momentum investors? Let's find out.

1 year ago · pennystocks.com

Best Penny Stocks To Buy Today? 4 To Watch Under $5

Penny stocks under $5 to watch this week. The post Best Penny Stocks To Buy Today?

1 year ago · pennystocks.com

Stock Market Today: Penny Stocks To Watch Amid Banking Crisis

Penny stocks to watch as bank stocks fall in the stock market today. The post Stock Market Today: Penny Stocks To Watch Amid Banking Crisis appeared first on Penny Stocks to Buy, Picks, News and Infor...

1 year ago · investorplace.com

Why Is IN8bio (INAB) Stock Up 9% Today?

IN8bio (NASDAQ: INAB ) stock is rising higher on Wednesday as the company's shares continue their wild swings this week. The strong movement for the stock started on Monday when shares experienced a 1...

1 year ago · proactiveinvestors.com

IN8bio stock price falls even as company receives FDA orphan drug status for brain cancer treatment

IN8bio (NASDAQ:INAB), Inc shares slid 16% to $2.51 in early Tuesday trading after the biopharmaceutical company announced that it has received orphan drug designation from the US Food and Drug Adminis...

1 year ago · investorplace.com

What Is Going on With In8bio (INAB) Stock Today?

In8bio (NASDAQ: INAB ) stock is on the move Tuesday as investors react to a recent rally and additional news from the biotechnology company. First off, investors will note that shares of INAB stock un...

2 years ago · 247wallst.com

11 Insiders Tip More Capital into IN8BIO and Broker HC Wainwright Initiates With Bullish $14 Target

Clinical stage biopharmaceutical company IN8bio Inc (US:INAB) topped the Fintel Significant Insider Buying Activity screen this week with 11 insiders buying over the last 90 days.

3 years ago · benzinga.com

IN8bio Stock Jumps After An Update From Leukemia Trial

IN8bio Inc (NASDAQ: INAB) has provided an update on the Phase 1 clinical trial of INB-100, a donor-derived gamma-delta T cell therapy for leukemia patients undergoing haploidentical hematopoietic stem...